The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia
Open Access
- 10 October 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 11 (1), 436
- https://doi.org/10.1186/1471-2407-11-436
Abstract
Background The clinical predictors of aromatase inhibitor-related arthralgia (AIA), a drug-related adverse reaction of aromatase inhibitors (AIs), remain unclear. Methods AIA was prospectively surveyed every 4 months in 328 postmenopausal breast cancer patients administered a non-steroidal AI (anastrozole). Various clinicopathological parameters were recorded and analyzed (chi-square test, Fisher's exact test and logistic regression analysis). Results The mean observation period was 39.9 months. AIA manifested in 114 patients (34.8%), with peaks of onset at 4 (33.7%) and 8 months (11.4%) after starting AI administration. Some cases manifested even after 13 months. AIA tended to occur in younger patients (incidences of 46.3%, 37.4% and 28.0% for ages of < 55, 55-65 and > 65 years, respectively (p = 0.063)) and decreased significantly with the age at menarche (53.3%, 35.3% and 15.4% for < 12, 12-15 and > 15 years, respectively (p = 0.036)). The incidences were 45.1%, 46.3 and 25.1% for the time since the last menstrual period (LMP) < 5 years, 5-10 years and > 10 years, being significantly lower at > 10 years (p < 0.001). In logistic regression analysis, the AIA incidence was significantly lower in the time since LMP > 10-year group versus the < 5-year group (odds ratio 0.44, p = 0.002), but the age at menarche showed no association. AIA manifested significantly earlier (≤ 6 months) as the time since LMP became shorter (< 5 years). Conclusion AIA tends to manifest early after starting AI, but some cases show delayed onset. The incidence was significantly lower in patients with a duration of > 10 years since LMP. When the time since LMP was short, the onset of AIA was significantly earlier after starting AI administration.Keywords
This publication has 26 references indexed in Scilit:
- Joint Symptoms, Aromatase Inhibitor-Related Adverse Reactions, Are Indirectly Associated with Decreased Serum EstradiolInternational Journal of Surgical Oncology, 2011
- Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivorsBreast Cancer Research, 2011
- Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancerBreast Cancer Research and Treatment, 2011
- A prospective study of aromatase inhibitor‐associated musculoskeletal symptoms and abnormalities on serial high‐resolution wrist ultrasonographyCancer, 2010
- Musculoskeletal Adverse Events Associated with Adjuvant Aromatase InhibitorsJournal of Oncology, 2010
- Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast CancerThe New England Journal of Medicine, 2009
- Patterns and risk factors associated with aromatase inhibitor‐related arthralgia among breast cancer survivorsCancer, 2009
- Getting a Grip on Aromatase Inhibitor–Associated ArthralgiasJournal of Clinical Oncology, 2008
- Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialThe Lancet, 2007
- Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98Journal of Clinical Oncology, 2007